Therapeutic Class

MilliporeSigma to acquire Netherlands-based organoid pioneer HUB MilliporeSigma to acquire Netherlands-based organoid pioneer HUB

The agreement is expected to close by the end of 2024, expanding MilliporeSigma’s service offerings.

byJosh Abbott, Editor, BioProcess Insider

Dec 18, 2024

|

1 Min Read

Therapeutic Class

CGT Catapult and UCL to develop digital twin for CAR-T manufacturing CGT Catapult and UCL to develop digital twin for CAR-T manufacturing

Dec 17, 2024

1 Min Read

Facilities & Capacity

Lonza calls time on capsules as mAbs and CGT drive core CDMO strategy Lonza calls time on capsules as mAbs and CGT drive core CDMO strategy

Dec 16, 2024

1 Min Read

Indonesia pledges $30m to Gavi to support global vaccinations Indonesia pledges $30m to Gavi to support global vaccinations

Dec 11, 2024

1 Min Read

Facilities & Capacity

Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO

Dec 9, 2024

1 Min Read

Therapeutic Class

Is India reliable? Addressing challenges in the pharma industry Is India reliable? Addressing challenges in the pharma industry

byShreeyashi Ojha

Dec 9, 2024

1 Min Read

Therapeutic Class

India’s pharma future relies on regulatory strength

India’s pharma future relies on regulatory strength

byShreeyashi Ojha, Reporter

Big Pharma, big CGT deals: Roche buying Poseida, Novartis buys Kate

Big Pharma, big CGT deals: Roche buying Poseida, Novartis buys Kate

byDan Stanton, Editorial director

Therapeutic Class

Novartis talks Leqvio manufacturing approach at TIDES Europe

Novartis talks Leqvio manufacturing approach at TIDES Europe

byDan Stanton, Editorial director

Vaccine makers sanguine amid threat from US health nominees RFK Jr. and Dr. Oz

Vaccine makers sanguine amid threat from RFK Jr. and Dr. Oz

byDan Stanton, Editorial director

Facilities & Capacity

CHOP teams with INCA to bring CAR-T therapies to children in Brazil

CHOP teams with INCA to bring CAR-T therapies to children in Brazil

byJosh Abbott, Editor, BioProcess Insider

Facilities & Capacity

CGT Catapult releases report on UK advanced therapy developments

CGT Catapult releases report on UK advanced therapy developments

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

CSL dedicated to Hemgenix as it turns back on lenti-based gene therapies

CSL dedicated to Hemgenix as it turns back on lenti-based gene therapies

byDan Stanton, Editorial director

Therapeutic Class

Repligen credits 10% revenue surge to new modalities and M&As

Repligen credits 10% revenue surge to new modalities and M&As

byShreeyashi Ojha, Reporter

Therapeutic Class

Meitheal adds three biosimilars to US offering with new agreement

Meitheal adds three biosimilars to US offering with new agreement

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

Post-pandemic dip: Panelists discuss CGT challenges

Post-pandemic dip: Panelists discuss CGT challenges

byShreeyashi Ojha, Reporter

Therapeutic Class

Artiva exec touts scalable NK cells to treat autoimmune diseases

Artiva exec touts scalable NK cells to treat autoimmune diseases

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

High tides: Lilly’s $20bn spend, Amgen preps network to enter GLP-1 space

High tides: Lilly’s $20bn spend, Amgen preps network to enter GLP-1 space

byDan Stanton, Editorial director

Facilities & Capacity

Governor unveils plans for $450m CGT innovation hub in New York

Governor unveils plans for $450m CGT innovation hub in New York

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

Investors prioritize efficacy in the CGT biz, experts say

Investors prioritize efficacy in the CGT biz, experts say

byShreeyashi Ojha, Reporter

Therapeutic Class

How and why AstraZeneca’s oncology eyes turned to cell therapies

How and why AstraZeneca turned to cell therapy for oncology

byDan Stanton, Editorial director

Facilities & Capacity

AtomVie partners with Radiopharm Ventures to produce radioantibody for trials

Radiopharm Ventures to produce radioantibody for AtomVie

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

USPs and efficacy driving CGT competitiveness

USPs and efficacy driving CGT competitiveness

byShreeyashi Ojha, Reporter

Therapeutic Class

Pheast partners with Lonza to produce cancer-gobbling CD24 drug

Pheast partners with Lonza to produce cancer-gobbling CD24 drug

byJosh Abbott, Editor, BioProcess Insider

Facilities & Capacity

Industry looks to distributed model to overcome cell therapy shortcomings

Industry looks to distributed model to overcome cell therapy shortcomings

byJosh Abbott, Editor, BioProcess Insider

CPC AseptiQuik

Sponsored Content

Maintaining Sterility Through CGT Processing and Cryopreservation

Maintaining Sterility Through CGT Processing and Cryopreservation

byBPI Contributor

Therapeutic Class

MSCRC awards $4.5m to Maryland scientists for stem-cell R&D

MSCRC awards $4.5m to Maryland scientists for stem-cell R&D

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

Vertex adds Lonza to cautious Casgevy commercial network

Vertex adds Lonza to cautious Casgevy commercial network

byDan Stanton, Editorial director

Planning, patient, and payer problems hurting gene therapy rollouts

Planning, patient, and payer problems hurting gene therapies

byDan Stanton, Editorial director

Therapeutic Class

Boston T-cell Party? Bioprocess industry flock to BWB

Boston T-cell Party? Bioprocess industry flock to BWB

byDan Stanton, Editorial director

Facilities & Capacity

Hongene and ReciBioPharm partner to improve gene-editing services

Hongene and ReciBioPharm partner to improve gene-editing services

byJosh Abbott, Shreeyashi Ojha

Upstream & Downstream Processing

Moving beyond protein translation with tRNA

Moving beyond protein translation with tRNA

byJosh Abbott, Millie Nelson

Boehringer Ingelheim bolsters veterinary pipeline with Saiba acquisition

Boehringer Ingelheim bolsters veterinary pipeline with Saiba acquisition

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

Hilleman and Bharat Biotech launch oral cholera vaccine in India

Hilleman and Bharat Biotech launch oral cholera vaccine in India

byJosh Abbott, Editor, BioProcess Insider

Therapeutic Class

Peering into the future of CAR-T cell therapies

Peering into the future of CAR-T cell therapies

byJosh Abbott, Editor, BioProcess Insider

Subscribe and receive the latest insights on the healthy food and beverage industry.

Join 47,000+ member. Yes, it's completely free.